source
- Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rivalBiotechs are sprinting to the IPO queue. In the industry's fourth IPO filing in two weeks, Braveheart Bio is seeking a Nasdaq listing to fuel Phase 3 testing of a cardio drug that could potentially…Endpoints · 15d ago↗ source
- Insilico, Bora Pharma reveal plans for AI-driven manufacturing companyInsilico Medicine and Taiwan-based CDMO Bora Pharmaceuticals are launching a new company with an AI-driven biologics manufacturing platform in a bid to compete with service providers headquartered…Endpoints · 15d ago↗ source
- Veradermics declares first efficacy win in women for hair loss drugVeradermics is for the first time reporting positive efficacy of its oral formulation of minoxidil in female pattern hair loss, which broadens the market potential of its flagship asset. In a mid-s…